Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
Amarin highlighted two data presentations at ACC.24 describing the effects of VASCEPA(R)/VAZKEPA on reducing MACE, or Major Adverse Cardiovascular Events, in patients with baseline high or low Lipoprotein(a) levels, as
— Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels — — Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –
Amarin announced that the Company received a Decision to Grant from the European Patent Office or EPO, for a new patent covering VAZKEPA or icosapent ethyl, that will extend VAZKEPA
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039